Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine

Overview

Journal Curr Neurol Neurosci Rep

Specialty Neurology

Date 2011 Jun 25

PMID 21701907

Citations 12

Authors

Manuel Comabella

Koen Vandenbroeck

Affiliations

Soon will be listed here.

Abstract

Notwithstanding the availability of disease-modifying treatments including interferon-β, glatiramer acetate, and natalizumab, a considerable proportion of multiple sclerosis (MS) patients experience continued progression of disease, clinical relapses, disease activity on MRI, and adverse effects. Application of gene expression, proteomic or genomic approaches is universally accepted as a suitable strategy toward the identification of biomarkers with predictive value for beneficial/poor clinical response to therapy and treatment risks. This review focuses on recent progress in research on the pharmacogenomics of disease-modifying therapies for MS. Although MS drug response biomarkers are not yet routinely implemented in the clinic, the diversity of reported, promising molecular markers is rapidly increasing. Even though most of these markers await further validation, given time, this research is likely to empower neurologists with an enhanced armamentarium to facilitate rational decisions on therapy and patient management.

Citing Articles

The Role of Cytotoxic T-Lymphocyte Antigen 4 in the Pathogenesis of Multiple Sclerosis.

Basile M, Bramanti P, Mazzon E Genes (Basel). 2022; 13(8).

PMID: 35893056 PMC: 9394409. DOI: 10.3390/genes13081319.

Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients.

Zarzuelo-Romero M, Perez-Ramirez C, Cura Y, Carrasco-Campos M, Marangoni-Iglecias L, Ramirez-Tortosa M J Pers Med. 2021; 11(10).

PMID: 34683173 PMC: 8540092. DOI: 10.3390/jpm11101032.

Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis.

Zarzuelo Romero M, Perez Ramirez C, Carrasco Campos M, Martin A, Calleja Hernandez M, Ramirez Tortosa M J Pers Med. 2021; 11(5).

PMID: 33922540 PMC: 8146426. DOI: 10.3390/jpm11050335.

Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.

Singh V, Tripathi A, Dutta R Proteomics. 2019; 19(16):e1800335.

PMID: 31119864 PMC: 6690771. DOI: 10.1002/pmic.201800335.

Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation.

Porcu G, Serone E, De Nardis V, Di Giandomenico D, Lucisano G, Scardapane M PLoS One. 2015; 10(12):e0144550.

PMID: 26658258 PMC: 4689554. DOI: 10.1371/journal.pone.0144550.

References

Carmona O, Masuet C, Santiago O, Alia P, Moral E, Alonso-Magdalena L . Multiple sclerosis and cognitive decline: is ApoE-4 a surrogate marker?. Acta Neurol Scand. 2011; 124(4):258-63. DOI: 10.1111/j.1600-0404.2010.01473.x. View

Gandhi K, McKay F, Diefenbach E, Crossett B, Schibeci S, Heard R . Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis. PLoS One. 2010; 5(5):e10484. PMC: 2864746. DOI: 10.1371/journal.pone.0010484. View

Patti F, Amato M, Bastianello S, Caniatti L, Di Monte E, Ferrazza P . Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler. 2009; 16(1):68-77. DOI: 10.1177/1352458509350309. View

Comi G . Treatment of multiple sclerosis: role of natalizumab. Neurol Sci. 2009; 30 Suppl 2:S155-8. DOI: 10.1007/s10072-009-0147-2. View

Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C . Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 2009; 16(2):208-17. DOI: 10.1177/1352458509355068. View

van Baarsen L, Vosslamber S, Tijssen M, Baggen J, van der Voort L, Killestein J . Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One. 2008; 3(4):e1927. PMC: 2271130. DOI: 10.1371/journal.pone.0001927. View

Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F . The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol. 2009; 16(4):528-36. DOI: 10.1111/j.1468-1331.2009.02532.x. View

Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E . Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics. 2007; 17(8):657-66. DOI: 10.1097/FPC.0b013e3281299169. View

Guerrero A, Tejero M, Gutierrez F, Martin-Polo J, Iglesias F, Laherran E . Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis. Neurologia. 2010; 26(3):137-42. DOI: 10.1016/j.nrl.2010.06.003. View

10.

Ma Q, Lu A . Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63(2):437-59. DOI: 10.1124/pr.110.003533. View

11.

Vosslamber S, van der Voort L, van den Elskamp I, Heijmans R, Aubin C, Uitdehaag B . Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis. Genes Immun. 2011; 12(6):466-72. DOI: 10.1038/gene.2011.18. View

12.

Martinez-Forero I, Pelaez A, Villoslada P . Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin Pharmacother. 2008; 9(17):3053-67. DOI: 10.1517/14656560802515553. View

13.

Serrano-Fernandez P, Moller S, Goertsches R, Fiedler H, Koczan D, Thiesen H . Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity. 2009; 43(2):172-8. DOI: 10.3109/08916930903219040. View

14.

Tran T, Paz P, Velichko S, Cifrese J, Belur P, Yamaguchi K . Interferonβ-1b Induces the Expression of RGS1 a Negative Regulator of G-Protein Signaling. Int J Cell Biol. 2011; 2010:529376. PMC: 3026965. DOI: 10.1155/2010/529376. View

15.

Bosca I, Villar L, Coret F, Magraner M, Simo-Castello M, Alvarez-Cermeno J . Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands. Mult Scler. 2010; 16(7):810-5. DOI: 10.1177/1352458510371961. View

16.

Axtell R, de Jong B, Boniface K, van der Voort L, Bhat R, De Sarno P . T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010; 16(4):406-12. PMC: 3042885. DOI: 10.1038/nm.2110. View

17.

Comabella M, Lunemann J, Rio J, Sanchez A, Lopez C, Julia E . A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009; 132(Pt 12):3353-65. DOI: 10.1093/brain/awp228. View

18.

Graham R, Kyogoku C, Sigurdsson S, Vlasova I, Davies L, Baechler E . Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 2007; 104(16):6758-63. PMC: 1847749. DOI: 10.1073/pnas.0701266104. View

19.

Byun E, Caillier S, Montalban X, Villoslada P, Fernandez O, Brassat D . Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol. 2008; 65(3):337-44. DOI: 10.1001/archneurol.2008.47. View

20.

Ford C, Goodman A, Johnson K, Kachuck N, Lindsey J, Lisak R . Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010; 16(3):342-50. PMC: 2850588. DOI: 10.1177/1352458509358088. View